Strategic Partnership with UnitedHealthcare
CNSide Diagnostics, a subsidiary of Plus Therapeutics, Inc. (NASDAQ: PSTV), has announced a national coverage agreement with UnitedHealthcare, part of UnitedHealth Group Inc. This landmark collaboration is aimed at expanding patient access to advanced diagnostic tools for central nervous system cancers.
Coverage Benefits for Patients
The agreement, which went into effect on September 15, ensures that over 51 million individuals across the United States will benefit from the CNSide Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT). This innovative diagnostic method is tailored for patients diagnosed with leptomeningeal metastases, significantly aiding in treatment decisions.
Enhancing Diagnostic Accuracy
The CNSide CSF Assay Platform is designed to facilitate rapid diagnoses, monitor treatment progression, and guide treatment plans. Its superior clinical utility has been validated through nine peer-reviewed studies and the FORESEE clinical trial, demonstrating practical application in real-world settings.
Significant Impact on Cancer Care
Since its introduction in 2020, more than 11,000 CNSide tests have been performed at over 120 cancer institutions nationwide. The high sensitivity (92%) and specificity (95%) of the CNSide test have influenced treatment decisions in an impressive 90% of cases, marking a substantial shift in how leptomeningeal metastases are managed.
Exclusive Testing Services
This advanced test is provided exclusively through CNSide Diagnostics, offering a vital resource for healthcare professionals in the United States. With the backing of UnitedHealthcare, access to this crucial testing service will potentially save more lives and improve patient outcomes.
Accreditation and Compliance
Recently, CNSide Diagnostics achieved a significant milestone by receiving a certificate of accreditation from CMS for its laboratory. This certification, awarded after a planned laboratory audit, confirms compliance with the Clinical Laboratory Improvement Amendments regulations mandated by the Centers for Medicare & Medicaid Services.
Accreditation guarantees that the laboratory meets rigorous standards for proficiency testing, personnel qualifications, and quality control, ultimately benefiting patients through improved diagnostic accuracy and reliable results.
Funding and Financial Support
In addition to expanding its diagnostic offerings, Plus Therapeutics announced an additional advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT). The recent $1.9 million payment contributes to the total award of $17.6 million previously granted by CPRIT and underscores the organization's commitment to supporting pioneering cancer research and treatment.
PSTV's Market Performance
As of recent trading sessions, Plus Therapeutics shares exhibited some volatility, declining 2.03% to $0.39 during premarket hours. The stock is approaching its 52-week low, indicating a critical period for the company as it navigates financial recovery while expanding its highly regarded diagnostic services.
Frequently Asked Questions
What is the significance of the partnership with UnitedHealthcare?
The agreement enhances patient access to CNSide diagnostic testing, benefiting millions and improving cancer care outcomes.
How does the CNSide CSF test work?
The test enumerates tumor cells in cerebrospinal fluid, assisting in diagnosis and treatment decisions for patients with CNS cancers.
What is the accuracy of the CNSide test?
It boasts a sensitivity of 92% and specificity of 95%, influencing treatment choices in 90% of cases.
Where are CNSide tests performed?
CNSide diagnostics are conducted in more than 120 cancer institutions across the U.S.
What financial support has Plus Therapeutics received recently?
The company has received an additional $1.9 million advance payment from CPRIT as part of a larger grant dedicated to cancer research initiatives.
